There is significant relationship between Beijing genotype family strains and resistance to the first-line anti-tuberculosis drugs in the Iranian population

被引：7
|
作者：
Keikha, Masoud [1 ,2 ,3 ]
机构：
[1] Mashhad Univ Med Sci, Antimicrobial Resistance Res Ctr, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Fac Med, Dept Microbiol & Virol, Mashhad, Razavi Khorasan, Iran
[3] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Razavi Khorasan, Iran
来源：
JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES | 2020年 / 19卷
关键词：
MYCOBACTERIUM-TUBERCULOSIS STRAINS; MULTIDRUG-RESISTANT; GENETIC DIVERSITY; ASSOCIATION; PREVALENCE; PATTERNS; MUTATIONS; LINEAGE; CHINA;
D O I：
10.1016/j.jctube.2020.100161
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The preparation of core/shell structured microsphere of multi first-line anti-tuberculosis drugs and evaluation of biological safety
    Zeng, Hao
    Pang, Xiaoyang
    Wang, Shuo
    Xu, Zhengquan
    Peng, Wei
    Zhang, Penghui
    Zhang, Yupeng
    Liu, Zheng
    Luo, Chengke
    Wang, Xiyang
    Nie, Hemin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (06): : 8398 - 8414
  • [42] Resistance to first-line tuberculosis drugs in three cities of Nigeria
    Lawson, L.
    Yassin, M. A.
    Abdurrahman, S. T.
    Parry, C. M.
    Dacombe, R.
    Sogaolu, O. M.
    Ebisike, J. N.
    Uzoewulu, G. N.
    Lawson, L. O.
    Emenyonu, N.
    Ouoha, J. O.
    David, J. S.
    Davies, P. D. O.
    Cuevas, L. E.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 (08) : 974 - 980
  • [43] High occurrence of simultaneous multiple-drug hypersensitivity syndrome induced by first-line anti-tuberculosis drugs
    Sim, Da Woon
    You, Hye Su
    Yu, Ji Eun
    Koh, Young-Il
    WORLD ALLERGY ORGANIZATION JOURNAL, 2021, 14 (07):
  • [44] Simultaneous determination of first-line anti-tuberculosis drugs by capillary zone electrophoresis using direct UV detection
    Faria, Adriana F.
    de Souza, Marcus V. N.
    Bruns, Roy E.
    de Oliveira, Marcone A. L.
    TALANTA, 2010, 82 (01) : 333 - 339
  • [45] Simultaneous analysis of first-line anti-tuberculosis drugs in tablets by UV spectrophotometry compared to capillary zone electrophoresis
    Marcellos, Luiza F.
    Faria, Adriana F.
    de Souza, Marcus V. N.
    Almeida, Mariana R.
    Sabin, Guilherme P.
    Poppi, Ronei J.
    de Oliveira, Marcone A. L.
    CENTRAL EUROPEAN JOURNAL OF CHEMISTRY, 2012, 10 (06): : 1808 - 1816
  • [46] Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study
    Prahl, Julie B.
    Johansen, Isik S.
    Cohen, Arieh S.
    Frimodt-Moller, Niels
    Andersen, Ase B.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (10) : 2841 - 2847
  • [47] Toxicity of the Increased Recommended Doses of First-line Anti-tuberculosis Oral Drugs in Children in a Reference Center in Spain
    Pereira, Laura
    Marco-Garcia, Monica
    Gamell, Anna
    Cuso, Teresa
    Monsonis, Manuel
    Latre, Cristina
    Fortuny, Claudia
    Noguera-Julian, Antoni
    ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (09): : 612 - 615
  • [48] Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid
    Yuhan Jiang
    Yixiao Li
    Cheng Liu
    Lei Zhang
    Danyu Lv
    Yejing Weng
    Zhongyi Cheng
    Xiangmei Chen
    Jun Zhan
    Hongquan Zhang
    Nature Communications, 12
  • [49] Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid
    Jiang, Yuhan
    Li, Yixiao
    Liu, Cheng
    Zhang, Lei
    Lv, Danyu
    Weng, Yejing
    Cheng, Zhongyi
    Chen, Xiangmei
    Zhan, Jun
    Zhang, Hongquan
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [50] Adverse drug reactions associated with first-line anti-tuberculosis drug regimens
    Marra, F.
    Marra, C. A.
    Bruchet, N.
    Richardson, K.
    Moadebi, S.
    Elwood, R. K.
    FitzGerald, J. M.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2007, 11 (08) : 868 - 875
12345